Search

Ioxaglic acid

Ioxaglic acid has a low osmolarity and is associated with fewer side effects compared to older contrast agents [L1883]. … Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opaque in its appearance on x-ray film, improving the visualization of important structures and organs during angiography, arteriography

Loperamide

Loperamide is an anti-diarrheal agent that is available as an over-the-counter product for treating diarrhea.[L42785] The drug was first synthesized in 1969 and used medically in 1976. … [A251610] It is a highly lipophilic synthetic phenylpiperidine opioid that works by binding to mu-opioid receptors on intestinal muscles to decrease intestinal motility and electrolyte loss.

Ferrous gluconate

Roflumilast

to be elucidated. … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.

Simethicone

Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. … [A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]

Methocarbamol

[A178450] Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts … [Label,L6268] In Canada, methocarbamol can be sold as an over the counter oral medicine at a lower dose that may be combined with [acetaminophen] or [ibuprofen].

Isoleucine

An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.

Bezisterim

Gastric intrinsic factor

on in the small intestine. … responsive to oral iron therapy.

Canagliflozin

It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897].